ESTEVE CDMO Expands Global Manufacturing Network with Major Investment in China

In a bold move to solidify its position as a leading contract development and manufacturing organization (CDMO), ESTEVE CDMO has announced an investment exceeding $80 million into expanding its manufacturing capabilities in China. This ambitious project signifies a pivotal moment for the organization, enhancing its infrastructure and output capabilities, while fostering closer connections with pharmaceutical partners throughout Asia.

Located in Shaoxing, the new manufacturing facility is designed to significantly bolster ESTEVE CDMO's production capacity. It features three state-of-the-art manufacturing workshops, which together encompass a total reaction volume of
250 m³. Looking ahead, the site has strategically allocated space to accommodate an additional 150+ m³, potentially elevating total reaction volume capacity to over 400 m³ as market demands evolve. This not only showcases ESTEVE's commitment to innovation but also ensures it can swiftly adapt to the growing needs of its partners.

Joan Petit, President of ESTEVE CDMO, articulated the company's vision: "This investment is a crucial step in our continued growth. It positions us to serve our customers more effectively in Asia by leveraging our global manufacturing network. Our goal is to establish a prominent international CDMO that is flexible and capable of meeting the complex demands of our pharmaceutical partners while supporting the essential mission of improving patient outcomes."

Advanced Manufacturing Technologies

The Shaoxing facility is not just about expansion; it's a testament to ESTEVE CDMO’s commitment to integrating advanced manufacturing technologies. The new site will feature a centralized control center designed for effective automation and digitalization, enhancing operational efficiency. Additionally, it will include comprehensive warehousing facilities and an office building, creating an environment where flexibility and responsiveness are paramount.

Integrated into ESTEVE's global manufacturing platform, the Shaoxing site will offer advanced technologies such as Spray Drying and High Potency Active Pharmaceutical Ingredient (HPAPI) manufacturing. This is crucial for meeting the increasingly complex requirements associated with small-molecule API development and production.

Commitment to Sustainability

In addition to enriching its manufacturing capabilities, ESTEVE has prioritized environmental sustainability in this project. The new facility has received a "Very Good" BREEAM rating, reflecting its sustainability performance and innovative design ethos. The project is also a nominee for the BREEAM China Awards, underscoring ESTEVE’s commitment to responsible manufacturing practices.

As a certified B Corp, ESTEVE is steadfast in its pledge to uphold high social and environmental standards, demonstrating transparency and accountability in its operations. The organization believes that combining economic growth with social responsibility is essential for creating a positive global impact.

A Legacy in China

ESTEVE CDMO’s journey in China began over two decades ago with its first joint venture established in 2000. This legacy has been marked by the establishment of strong local capabilities and collaborations, making ESTEVE a notable player in the high-end API manufacturing landscape. Francisco de Asís Benítez Salas, the Spanish Consul General in Shanghai, acknowledged the significance of ESTEVE’s long-term commitment to China, stating, "This investment exemplifies how sustained dedication and innovation can benefit the local community."

As part of ESTEVE's extensive global manufacturing network—which includes operations in Europe, the Americas, and now a significantly enhanced presence in Asia—this investment in China signals a continued commitment to local expertise while enabling ESTEVE CDMO to cater effectively to its customers across international markets.

In conclusion, as ESTEVE CDMO moves forward with its expansion in China, it remains dedicated to leveraging its extensive experience and cutting-edge technology to support pharmaceutical partners in overcoming the complexities of drug development, reinforcing its purpose of improving lives through collaborative innovation.